

Special Issue

Cardiovascular Disease and COVID-19

Message from the Guest Editor

Cardiovascular disease is frequently found in patients with COVID-19. Arrhythmias, myocarditis, worsening heart failure, pulmonary embolism, cerebrovascular accidents, and peripheral vascular disease can affect patients infected with SARS-CoV-2 virus. In addition, cardiovascular disease has also been, although very rarely, associated with vaccination against this disease. Furthermore, the potential for cardiovascular involvement in long-COVID-19 is a real threat. Consequently, studies on the subjects raised above focusing on the immunological aspects of the disease are welcome. This Special Issue aims to provide knowledge to doctors at the frontline on the SARS-CoV-2-induced cardiovascular disease. Therefore, I am pleased to invite you to take part in this challenging task. For this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: epidemiological, pathologic, clinical manifestations, subsidiary exam, clinical course, and treatment of SARS-CoV-2-induced cardiovascular disease. I look forward to receiving your contributions.

Guest Editor

Dr. Reinaldo Bulgarelli Bestetti

Department of Medicine, University of Ribeirao Preto, Ribeirao Preto, Brazil

Deadline for manuscript submissions

closed (31 August 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/125762

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).